Mar. 17 at 4:51 PM
$CVKD Back in December they added another drug with FDA fast track Orphan drug designation into their pipeline (CAD-1005), formerly known as VLX-1005
The market for (CAD-1005) which treats Heparin-Induced Thrombocytopenia (HIT) is in the range of
$1B
FDA meeting this month “March”. End-of-Phase 2 Meeting to align a Phase 3 registration path
Phase 2 trial of CAD-1005 for Heparin-Induced Thrombocytopenia (HIT) showed encouraging results, with a 50% reduction in new or worsening thrombotic events compared to a high (>75%) rate in the placebo group
And this
$1B market opportunity is on top of their other FDA orphan drug Tecarfarin which has a
$2B market opportunity
